UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 9, 2025
Vivani Medical, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
Delaware
|
|
001-36747
|
|
02-0692322
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
1350 S. Loop Road
Alameda, California 94502
(Address of principal executive offices, including zip code)
(415) 506-8462
(Telephone number, including area code, of agent for service)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
|
☐
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
☐
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
☐
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
|
Common Stock, par value $0.0001 per share
|
|
VANI
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation
FD Disclosure
Vivani
Medical, Inc. (the “Company”) from time to time presents and/or distributes to
the investment community at various industry and other conferences slide
presentations to provide updates and summaries of its business. These slides
are attached to this Current Report on Form 8-K as Exhibit 99.1 and are
incorporated by reference herein. The Company is also posting to the
“Investors” portion of its website a copy of its current corporate slide
presentation. The slides speak as of the date of this Current Report on Form
8-K. While the Company may elect to update the slides in the future or reflect
events and circumstances occurring or existing after the date of this Current
Report on Form 8-K, the Company specifically disclaims any obligation to do so.
The
information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be
deemed “filed” for purposes of Section 18 of the Exchange Act, or incorporated
by reference in any filing under the Securities Act, whether made before or
after the date hereof, or the Exchange Act, except as shall be expressly set forth
by reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
Corporate
Slides as of September 9, 2025.
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
VIVANI MEDICAL, INC.
|
|
|
|
|
|
Date: September 9, 2025
|
By:
|
/s/ Donald Dwyer
|
|
|
Name:
|
Donald Dwyer
|
|
|
Title:
|
Chief Business Officer
|
